TY - JOUR
T1 - Interim analysis of a multicenter registry study of COVID-19 patients with inflammatory bowel disease in Japan (J-COSMOS)
AU - J-COSMOS group
AU - Nakase, Hiroshi
AU - Hayashi, Yuki
AU - Hirayama, Daisuke
AU - Matsumoto, Takayuki
AU - Matsuura, Minoru
AU - Iijima, Hideki
AU - Matsuoka, Katsuyoshi
AU - Ohmiya, Naoki
AU - Ishihara, Shunji
AU - Hirai, Fumihito
AU - Abukawa, Daiki
AU - Hisamatsu, Tadakazu
AU - Sasaki, Makoto
AU - Iizuka, Masahiro
AU - Fujiya, Mikihiro
AU - Kinjo, Fukunori
AU - Nakamura, Shiro
AU - Kamata, Noriko
AU - Etani, Yuri
AU - Ueno, Fumiaki
AU - Hiraoka, Sakiko
AU - Kondo, Takeo
AU - Kagaya, Takashi
AU - Naganuma, Makoto
AU - Kobayashi, Kiyonori
AU - Kobayashi, Taku
AU - Yamamoto, Shuji
AU - Naito, Yuji
AU - Furuta, Yoki
AU - Mitsuyama, Keichi
AU - Hashimoto, Yu
AU - Arai, Katsuhiro
AU - Kato, Shingo
AU - Iwama, Itaru
AU - Esaki, Motohiro
AU - Tanaka, Hiroki
AU - Nakase, Hiroshi
AU - Motoya, Satoshi
AU - Maemoto, Atsuo
AU - Ashida, Tomofumi
AU - Nishimata, Nobuaki
AU - Andoh, Akira
AU - Yamamoto, Hironori
AU - Shimizu, Toshiaki
AU - Maeda, Yasuharu
AU - Kinoshita, Kenji
AU - Fukuda, Katuyuki
AU - Kato, Jun
AU - Takeuchi, Ken
AU - Nagahori, Masakazu
N1 - Publisher Copyright:
© 2022, The Author(s).
PY - 2022/3
Y1 - 2022/3
N2 - Background: The spread of coronavirus disease 2019 (COVID-19) had a major impact on the health of people worldwide. The clinical background and clinical course of inflammatory bowel disease (IBD) among Japanese patients with COVID-19 remains unclear. Methods: This study is an observational cohort of Japanese IBD patients diagnosed with COVID-19. Data on age, sex, IBD (classification, treatment, and activity), COVID-19 symptoms and severity, and treatment of COVID-19 were analyzed. Results: From 72 participating facilities in Japan, 187 patients were registered from June 2020 to October 2021. The estimated incidence of COVID19 in Japanese IBD patients was 0.61%. The majority of IBD patients with COVID-19 (73%) were in clinical remission. According to the WHO classification regarding COVID-19 severity, 93% (172/184) of IBD patients had non-severe episodes, while 7% (12/184) were severe cases including serious conditions. 90.9% (165/187) of IBD patients with COVID-19 had no change in IBD disease activity. A logistic regression analysis stepwise method revealed that older age, higher body mass index (BMI), and steroid use were independent risk factors for COVID-19 severity. Six of nine patients who had COVID-19 after vaccination were receiving anti-tumor necrosis factor (TNF)-α antibodies. Conclusion: Age, BMI and steroid use were associated with COVID-19 severity in Japanese IBD patients.
AB - Background: The spread of coronavirus disease 2019 (COVID-19) had a major impact on the health of people worldwide. The clinical background and clinical course of inflammatory bowel disease (IBD) among Japanese patients with COVID-19 remains unclear. Methods: This study is an observational cohort of Japanese IBD patients diagnosed with COVID-19. Data on age, sex, IBD (classification, treatment, and activity), COVID-19 symptoms and severity, and treatment of COVID-19 were analyzed. Results: From 72 participating facilities in Japan, 187 patients were registered from June 2020 to October 2021. The estimated incidence of COVID19 in Japanese IBD patients was 0.61%. The majority of IBD patients with COVID-19 (73%) were in clinical remission. According to the WHO classification regarding COVID-19 severity, 93% (172/184) of IBD patients had non-severe episodes, while 7% (12/184) were severe cases including serious conditions. 90.9% (165/187) of IBD patients with COVID-19 had no change in IBD disease activity. A logistic regression analysis stepwise method revealed that older age, higher body mass index (BMI), and steroid use were independent risk factors for COVID-19 severity. Six of nine patients who had COVID-19 after vaccination were receiving anti-tumor necrosis factor (TNF)-α antibodies. Conclusion: Age, BMI and steroid use were associated with COVID-19 severity in Japanese IBD patients.
KW - Anti-TNF-α antibodies
KW - COVID-19
KW - Inflammatory bowel disease
KW - SARS-CoV-2
KW - Steroid
UR - http://www.scopus.com/inward/record.url?scp=85125553957&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85125553957&partnerID=8YFLogxK
U2 - 10.1007/s00535-022-01851-1
DO - 10.1007/s00535-022-01851-1
M3 - Article
C2 - 35089397
AN - SCOPUS:85125553957
SN - 0944-1174
VL - 57
SP - 174
EP - 184
JO - Journal of Gastroenterology
JF - Journal of Gastroenterology
IS - 3
ER -